3 - 9 November 2018
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
The effect of pregnancy on MS
Pregnancy will alter the relapse rate of women with MS according to a new study. The results, based on health records of more than 2,000 women found that relapse rate fell during pregnancy, spiked in the six week period after delivery and then returned to pre-pregnancy levels.
Source: National MS Society (USA)
MS Trust link: Pregnancy
Ocrevus for PPMS decision paused
The final decision on whether Ocrevus (ocrelizumab) will be available for people with primary progressive MS in England has been paused for more discussion between NICE and Roche, who make the drug. NICE had been due to recommend that the drug was not cost effective
Source: MS News Today
MS Trust link: Ocrevus (ocrelizumab)
Coexisting conditions affect atrophy
EMA recommends temporary restriction on use of Lemtrada
12 April 2019
The European Medicines Agency has recommended a temporary restriction on people who should start treatment with Lemtrada while a review of side effects is carried out.
How fundraising for the MS Trust helps me to help my daughter
12 April 2019
Nick is taking part in the Great North Run for the third time in September and this year his daughter Amie will be joining him on Team MS Trust for her first half marathon. Here, Nick and Amie tell us about the inspiration behind their fundraising.